This discussion between Dr. Ursula Matulonis and Dr. Mansoor Mirza provides valuable insights into the recent advancements in the treatment of advanced endometrial cancer using immunotherapy.
The key highlights include:
The RUBY study demonstrated that the addition of the checkpoint inhibitor dostarlimab to standard chemotherapy (carboplatin-paclitaxel) resulted in a 72% reduction in the risk of disease progression and a 70% reduction in the risk of death for patients with mismatch repair-deficient (dMMR) endometrial cancer. Similar benefits were also seen in the mismatch repair-proficient (pMMR) population.
The NRG-GY018 and DUO-E trials also showed positive results with the addition of pembrolizumab and durvalumab, respectively, to chemotherapy for advanced endometrial cancer. These three checkpoint inhibitors are now FDA-approved for use in this setting.
The experts discussed the challenges in determining the optimal duration of immunotherapy, as the trials had different treatment durations. While the dMMR population appears to benefit from shorter treatment durations, the pMMR population may require longer maintenance therapy.
Beyond immunotherapy, the experts also discussed the potential role of other novel therapies, such as CDK4/6 inhibitors and antibody-drug conjugates, in the management of advanced endometrial cancer.
The discussion highlights the rapid progress in the field and the need for continued research to further refine the treatment approach and optimize outcomes for patients with this challenging disease.
toiselle kielelle
lähdeaineistosta
www.medscape.com
Tärkeimmät oivallukset
by Ursula A. Ma... klo www.medscape.com 09-25-2024
https://www.medscape.com/viewarticle/999852Syvällisempiä Kysymyksiä